Curanex Pharmaceuticals Inc — financial distress indicators
Financial-health summary
Curanex Pharmaceuticals Inc's reported numbers place it in the 'Watch' financial-health band (distress score 36/100). The main indicators are operations consume cash, ohlson o-score signals likely failure and losses in 2 of the last 2 years. Independently, the Ohlson accounting model puts its 1-year failure probability at 100% and the market-implied (Merton) default probability is 0.2%. In its favour: cash on hand covers all debt (net-cash balance sheet).
Stress by dimension
Share price — last 12 months
Indicators behind the score
Each red flag shows the evidence from the company’s own filings and the financial or legal principle behind it. Points add to the 0–100 score.
Operating cash flow negative in 2 of the last 2 years.
A business that cannot fund itself from operations depends on external capital to survive.
O-score 30.00 → model probability 100%.
Ohlson (1980) logit model of 1-year corporate failure; O > 0 (p > 50%) is the original failure cut-off.
Recurring net losses.
Repeated losses are a core input in both Ohlson and Altman failure models.
Price is -70% from its 52-week high.
For financial firms a share-price run often precedes a deposit or funding run (confidence channel).
0 severe and 1 moderate distress-related headlines in the last 6 months.
Headlines are corroborating evidence only; they are weighted lightly and never drive a flag alone.
Revenue vs net income
Cash generation
Debt vs cash vs equity
✅ Mitigating factors
- Cash on hand covers all debt (net-cash balance sheet).
- Strong current ratio (62.87).
- High insider/promoter ownership (61%) aligns management with survival.
📰 Recent news scan
- fraudWolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims on behalf of the shareholders of Curanex Pharmaceuticals Inc. (NASDAQ: CURX) - Barchart.comGoogle News · 2026-05-18
- CURX S-1/A & SEC Filings - Yahoo! Finance CanadaGoogle News · 2026-10-04
- CURX 8-K & SEC Filings - Yahoo! Finance CanadaGoogle News · 2026-10-01
- Curanex Pharmaceuticals (CURX) Edges Up 3.68% as Micro-Cap Biotech Holds Key Support - Support Level Bounce - www.dars.gov.etGoogle News · 2026-08-12
- T-CURX buys Pantherna as the race for in vivo CAR-T gathers pace - European Biotechnology MagazineGoogle News · 2026-06-01
⚖️ U.S. legal pathway — Title 11, U.S. Code
Which chapter would apply?
- Chapter 11 — reorganisation. Management usually stays in control as debtor-in-possession; the automatic stay (§362) halts collection; a plan must meet the best-interests test (§1129(a)(7)) and the absolute priority rule (§1129(b)) — creditors are paid before shareholders, who are frequently wiped out.
- Chapter 7 — liquidation. A trustee sells assets and distributes proceeds by statutory priority (§§507, 726).
- Subchapter V (“Chapter 5”) is a fast track for small-business debtors under a statutory debt cap, but SEC-reporting companies are excluded (§101(51D)) — so it rarely applies to listed companies.
What typically triggers a filing
- Payment default or covenant breach lenders will not waive; a debt maturity that cannot be refinanced.
- Auditor going-concern doubt (ASC 205-40 / PCAOB AS 2415) — often itself a default trigger in loan agreements.
- Creditors can force a case with an involuntary petition (§303) if debts are not paid as they come due.
- Delisting after sustained sub-$1 prices or equity deficits cuts off equity funding.
Transactions shortly before filing can be clawed back (preferences — 90 days, §547; fraudulent transfers — 2 years, §548).
Frequently asked questions
What do Curanex Pharmaceuticals Inc's financial-health indicators show?
As of 2026-10-08, Curanex Pharmaceuticals Inc's public financial data places it in the 'Watch' band with a distress score of 36/100, driven by operations consume cash, ohlson o-score signals likely failure and losses in 2 of the last 2 years. This is a statistical screen of reported numbers — it does not mean the company is insolvent, has defaulted or will enter insolvency proceedings.
What is Curanex Pharmaceuticals Inc's financial distress score?
36/100 ('Watch'). Ohlson O-score 30.0 (model 1-year failure probability 100%). Merton distance-to-default 2.94 σ (model default probability 0.2%).
What works in Curanex Pharmaceuticals Inc's favour?
Cash on hand covers all debt (net-cash balance sheet). Strong current ratio (62.87). High insider/promoter ownership (61%) aligns management with survival.
How are shareholders treated if a company enters insolvency?
In a Chapter 11 reorganisation the absolute priority rule pays secured lenders, then unsecured creditors, before shareholders — so existing shares are usually cancelled or heavily diluted. In Chapter 7 the company is liquidated and shareholders rarely recover anything.
Other Pharma & Biotech companies with distress indicators
- ABVC BioPharma, Inc. (ABVC)Very weak 100/100
- AKAN (AKAN)Very weak 100/100
- Endovia Health Sciences, Inc. (EDVA)Very weak 100/100
- Elicio Therapeutics, Inc. (ELTX)Very weak 100/100
- IM Cannabis Corp. (IMCC)Very weak 100/100
- NeuroSense Therapeutics Ltd. (NRSN)Very weak 100/100
Methodology
Score = capped sum of rule-based red flags across seven dimensions (liquidity, solvency, profitability, cash flow, sales trend, market signal, news). Ohlson O-score (1980) gives an accounting-based 1-year failure probability; Merton distance-to-default (Bharath & Shumway 2008) gives a market-implied probability. Financial institutions use a capital-based rule set. Recalculated every trading day from the latest filings, prices and news.